Aethlon Medical, Inc. (NASDAQ:AEMD) Short Interest Update

Aethlon Medical, Inc. (NASDAQ:AEMD) was the target of a large decrease in short interest in August. As of August 14th, there was short interest totaling 65,075 shares, a decrease of 71.9% from the July 30th total of 231,654 shares. Based on an average daily volume of 65,331 shares, the days-to-cover ratio is currently 1.0 days. Currently, 9.2% of the company’s shares are sold short.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the stock. HC Wainwright reissued a “neutral” rating and issued a $1.50 price target on shares of Aethlon Medical in a research note on Tuesday, August 18th. Wall Street Zen raised Aethlon Medical to a “sell” rating in a research report on Saturday, August 8th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Aethlon Medical in a research report on Friday, July 17th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Reduce” and an average target price of $1.50.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Aethlon Medical stock. Citadel Advisors LLC bought a new position in Aethlon Medical, Inc. (NASDAQ:AEMD) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned approximately 36.57% of Aethlon Medical at the end of the most recent quarter. 1.99% of the stock is owned by hedge funds and other institutional investors.

Aethlon Medical Stock Performance

Shares of Aethlon Medical stock traded down $0.11 during trading on Thursday, hitting $2.17. The company’s stock had a trading volume of 12,807,472 shares, compared to its average volume of 102,264. Aethlon Medical has a 52 week low of $2.17 and a 52 week high of $105.00. The company has a market capitalization of $1.54 million, a PE ratio of -0.06 and a beta of 1.41. The company has a fifty day simple moving average of $3.68 and a two-hundred day simple moving average of $8.19.

Aethlon Medical (NASDAQ:AEMD) last posted its quarterly earnings data on Thursday, August 13th. The medical equipment provider reported ($4.02) EPS for the quarter, missing the consensus estimate of ($3.92) by ($0.10). As a group, analysts predict that Aethlon Medical will post -5.74 EPS for the current year.

About Aethlon Medical

Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.

The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.